Date: 12/11/2022
Category:

Poster: Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Recent updates

View all updates

View Career Opportunities

Career Opportunities

The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.

X
Concerning Your Privacy
Access to an Ichnos Site may be monitored by Ichnos. If monitored, the requesting URLs, the machine originating the request and the time of the request are logged for access statistics and security purposes. Your use and access of an Ichnos Site constitutes your consent to such general monitoring. Please see the Ichnos Privacy Policy and Cookie Notice for details on how information from the Site may be gathered and used.